Prepared By R.R. Donnelley Financial -- Form 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): 09/28/2012
CORTEX PHARMACEUTICALS INC/DE/
(Exact name of registrant as specified in its charter)
Commission File Number: -
|
DE
|
|
330303583
|
|
(State or other jurisdiction of
|
|
(IRS Employer
|
|
incorporation)
|
|
Identification No.)
|
7700 Irvine Center Drive, Suite 750, Irvine, CA 92618
(Address of principal executive offices, including zip code)
949 727 3157
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Effecitve September 28, 2012 and October 1, 2012, respectively, Peter W. Letendre, Pharm.D. and David W. Carley, Ph.D. resigned as members of the Board of Directors of Cortex Pharmaceuticals, Inc.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
|
|
|
|
CORTEX PHARMACEUTICALS INC/DE/
|
|
|
|
|
|
Date: October 04, 2012
|
|
|
|
By:
|
|
/s/ Maria S. Messinger
|
|
|
|
|
|
|
|
|
|
Maria S. Messinger
|
|
|
|
|
|
|
|
|
|
Vice President and Chief Financial Officer
|
|
|
|
|